Compare CFFN & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFN | BBNX |
|---|---|---|
| Founded | 1893 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 997.9M |
| IPO Year | 2010 | 2025 |
| Metric | CFFN | BBNX |
|---|---|---|
| Price | $8.44 | $16.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 15 |
| Target Price | $9.50 | ★ $25.10 |
| AVG Volume (30 Days) | ★ 1.1M | 1.0M |
| Earning Date | 10-28-2026 | 10-27-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | ★ 79.31 | 78.95 |
| EPS | ★ 0.51 | N/A |
| Revenue | $16,300,000.00 | ★ $100,251,000.00 |
| Revenue This Year | $7.98 | $25.28 |
| Revenue Next Year | $4.98 | $47.19 |
| P/E Ratio | $16.70 | ★ N/A |
| Revenue Growth | 6.54 | ★ 53.94 |
| 52 Week Low | $5.98 | $8.80 |
| 52 Week High | $9.26 | $32.71 |
| Indicator | CFFN | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 50.26 | 41.87 |
| Support Level | $8.43 | $15.92 |
| Resistance Level | $8.76 | $18.20 |
| Average True Range (ATR) | 0.19 | 1.34 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 68.46 | 8.88 |
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.